Why the study?
Pulmonary hypertension shares the common feature of mitochondrial dysfunction across classifications, but its role in pulmonary vascular remodeling and available therapeutic options warrant comprehensive review.
This review highlights the central role of mitochondrial dysfunction in the pathophysiology of pulmonary hypertension and discusses potential mitochondria-targeted therapeutic options.
Answers are grounded in this paper and cite their sources.
Mitochondrial dysfunction unifies PH mechanisms; leaves open antioxidant targeting before clinical adoption.
Pulmonary hypertension (PH) is a multi-etiological condition with a similar hemodynamic clinical sign and end result of right heart failure. Although its causes vary, a similar link across all the classifications is the presence of mitochondrial dysfunction. Mitochondria, as the powerhouse of the cells, hold a number of vital roles in maintaining normal cellular homeostasis, including the pulmonary vascular cells. As such, any disturbance in the normal functions of mitochondria could lead to major pathological consequences. The Warburg effect has been established as a major finding in PH conditions, but other mitochondria-related metabolic and oxidative stress factors have also been reported, making important contributions to the progression of pulmonary vascular remodeling that is commonly found in PH pathophysiology. In this review, we will discuss the role of the mitochondria in maintaining a normal vasculature, how it could be altered during pulmonary vascular remodeling, and the therapeutic options available that can treat its dysfunction.
No takes yet. Share an insight, caveat, or question.
Ryanto et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: